Lataa...
Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities
Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest cancer in the US by 2025 (1), with 5-year survival at less than 10% (2). In other recalcitrant cancers, immunotherapy has shown unprecedented response rates, including durable remissions after drug discontinuation. H...
Tallennettuna:
| Julkaisussa: | Gastroenterology |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6486864/ https://ncbi.nlm.nih.gov/pubmed/30660727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2018.12.038 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|